Consequently, after exclusion of SCLC-P tumors, high NOTCH1 expression was associated with significantly longer OS with atezolizumab compared with placebo (HR 0.59; 95% CI, 0.39–0.90; unadjusted P = 0.01) among the remaining IMpower133 dataset, whereas low NOTCH1 expression was not (HR 0.88; 95% CI, 0.59–1.31; unadjusted P = 0.51) (Figure 2D). Here, NOTCH1 is linked to small cell lung carcinoma.